Fluoroquinolones and Gram-negative bacteria: Antimicrobial activity and mechanisms of resistance;Fluorochinoloni e Gram-negativi: Differenze di attività e nuove evidenze sui meccanismi di resistenza

Infezioni in Medicina

Volumn 16, Issue SUPP. 2, 2008, Pages 5-11

  Luzzaro, F ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Fluoroquinolones; Gram negatives; Mechanism of resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL PROTEIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; DRUG MECHANISM; ENTEROBACTER; ENZYME ACTIVITY; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; REVIEW;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; NUCLEIC ACID SYNTHESIS INHIBITORS; R FACTORS;

EID: 54349092372     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Mascaretti O.A. Inhibitors of DNA gyrase and topoisomerase IV: quinolones. In: Bacteria versus antibacterial agents: an integrated approach, 295-309, 2003, ASM press, Washington, DC.
2. Tumbarello M., Sanguinetti M., Montuori E. et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51, 6, 1987-1994, 2007.
3. Robicsek A., Jacoby G.A., Hooper D.C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6, 10, 629-640, 2006.
4. Jacoby G.A. Beta-lactamase nomenclature. Antimicrob. Agents Chemother. 50, 4, 1123-1129, 2006.
5. Cattoir V., Poirel L., Nordmann P. Plasmid-mediated quinolone resistance determinant qnrB4 in France from an Enterobacter cloacae clinical isolate co-expressing a qnrS1 determinant. Antimicrob. Agents Chemother. 60, 2, 394-397, 2007.
6. Jacoby G.A. Mechanisms of resistance to quinolones. Clin. Infect. Dis. suppl. 2, 15, 41, S120-S126, 2005.
7. Rodrìguez-Martìnez J.M., Velasco C., Garcìa I., Cano M.E. Mutant Prevention Concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob. Agents Chemother. 51, 2236-2239, 2007.
8. Robicsek A., Jacoby G.A., Hooper D.C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6, 629-640, 2006.
9. Robicsek A., Strahilevitz J., Jacoby G.A. et al. Fluoroquinolone- modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nature Medicine 12, 1, 83-88, 2006.
10. Park C.H., Robicsek A., Jacoby G.A., Sahm D., Hooper D.C. Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob. Agents Chemother. 50, 3953-3955, 2006.
11. Pèrichon B., Courvalin P., Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob. Agents Chemother. 51, 7, 2464-2469, 2007.